Emerging hormonal agents for the treatment of prostate cancer
Sign Up to like & getrecommendations! Published in 2022 at "Expert Opinion on Emerging Drugs"
DOI: 10.1080/14728214.2022.2121390
Abstract: ABSTRACT Introduction Prostate cancer is the most common solid organ malignancy in men in the United States. Until recently, treatment options for men with metastatic disease were limited and patients faced poor outcomes with minimal… read more here.
Keywords: prostate cancer; hormonal agents; emerging hormonal; treatment ... See more keywords
Comparative cardiotoxicity of the novel hormonal agents abiraterone and enzalutamide in metastatic castration-resistant prostate cancer using real-world data.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.6_suppl.62
Abstract: 62Background: Novel hormonal agents (NHAs) such abiraterone (ABI) and enzalutamide (ENZA) have demonstrated similar survival benefits against placebo groups in their respective clinical trials lead... read more here.
Keywords: novel hormonal; abiraterone enzalutamide; agents abiraterone; cardiotoxicity novel ... See more keywords
Utilization Trends of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer in Quebec
Sign Up to like & getrecommendations! Published in 2022 at "Current Oncology"
DOI: 10.3390/curroncol29110680
Abstract: Background: The introduction of novel hormonal agents (NHAs) such as abiraterone acetate (ABI) and enzalutamide (ENZ) for metastatic castration-resistant prostate cancer (mCRPC) was an important milestone given their survival benefits, tolerability, and ease of administration… read more here.
Keywords: oncology; hormonal agents; novel hormonal; castration resistant ... See more keywords